Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma × temsirolimus × Clear all

Phase

Status

Sponsor Class

NIH 2 OTHER 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 8 Neoplasms 5 Lymphoma, Mantle-Cell 4 Breast Neoplasms 4 Kidney Neoplasms 3 Neoplasm Metastasis 2 Lung Neoplasms 2 Carcinoma 2 Urogenital Neoplasms 1 Solid Tumors 1 Prostatic Neoplasms 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Colonic Neoplasms 1 Carcinoma, Squamous Cell 1 Adenocarcinoma 1

Interventions

Rituximab 63 Cyclophosphamide 37 Brentuximab Vedotin 22 Bendamustine Hydrochloride 22 fludarabine 20 Gemcitabine 20 Doxorubicin 20 pembrolizumab 19 Prednisone 19 ibrutinib 17 Vincristine 16 obinutuzumab 14 Lenalidomide 13 Nivolumab 10 Rifampin 8 parsaclisib 7 duvelisib 7 atezolizumab 7 Vorinostat 7 Dexamethasone 7 Azacitidine 7 spartalizumab 6 loncastuximab tesirine 6 MLN 8237 6 venetoclax 5 ixazomib 5 glofitamab 5 fludarabine phosphate 5 durvalumab 5 acalabrutinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00117598 2015-03-30

OPTIMAL

Pfizer

Phase 3 Completed

169 enrolled 15 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡